Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STAT6 | P42226 | 1/20 | 0.43 |
| ▸ | F10 | P00742 | 5/20 | 0.42 |
| ▸ | NTRK1 | P04629 | 4/20 | 0.41 |
| ▸ | SYK | P43405 | 2/20 | 0.40 |
| ▸ | JAK3 | P52333 | 3/20 | 0.40 |
| ▸ | JAK2 | O60674 | 3/20 | 0.39 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.39 |
| ▸ | F2 | P00734 | 1/20 | 0.38 |
| ▸ | ELANE | P08246 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | JAK1 | P23458 | 1/20 | 0.38 |
| ▸ | TYK2 | P29597 | 1/20 | 0.38 |
| ▸ | GFER | P55789 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17021376 | 0.93 | STAT6 (0.48) | STAT6F10NTRK1SYKJAK3 | |
| SCHEMBL17021343 | 0.88 | STAT6 (0.44) | STAT6F10NTRK1SYKJAK3 | |
| SCHEMBL19010329 | 0.87 | SYK (0.42) | STAT6F10SYKJAK3JAK2 | |
| SCHEMBL19010269 | 0.86 | STAT6 (0.57) | STAT6NTRK1JAK3JAK2CCNT1 | |
| SCHEMBL19010276 | 0.85 | GFER (0.54) | STAT6NTRK1SYKJAK3POLB | |
| SCHEMBL19010325 | 0.85 | STAT6 (0.46) | STAT6NTRK1JAK3JAK2JAK1 | |
| SCHEMBL19010268 | 0.83 | JAK3 (0.46) | STAT6NTRK1JAK3JAK2POLB | |
| SCHEMBL19010307 | 0.81 | PTK2 (0.41) | NTRK1JAK3TDP1 | |
| SCHEMBL17021340 | 0.80 | SYK (0.47) | STAT6F10SYKJAK3JAK2 | |
| SCHEMBL17021284 | 0.79 | GFER (0.52) | STAT6NTRK1SYKJAK3TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9834548-B2 | Pyridazine compounds as JAK inhibitors | PORTOLA PHARMACEUTICALS, INC. (US) | 2017-12-05 | — | — | US | disclosed |
| US-20170174673-A1 | PYRIDAZINE COMPOUNDS AS JAK INHIBITORS | ALEXION PHARMACEUTICALS, INC. | 2017-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170174673-A1 | PYRIDAZINE COMPOUNDS AS JAK INHIBITORS | JAK1, JAK2, JAK3 | STAT6 8/4885F10 2668/4885NTRK1 1410/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.